Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame
Primary	Hematologic remission rate	Week 12,24
Secondary	Molecular remission rate	Week 24,48
Secondary	Peripheral blood driver genes	Week 24,48
Secondary	Bone marrow-driven genes	Week 24,48
Secondary	The incidence of thrombosis	Week 24,48
Secondary	Incidence of bleeding events	Week 24,48
Secondary	The incidence of progression to myelofibrosis.	Week 24,48
Secondary	The incidence of acute leukemia.	Week 24,48
Secondary	Changes in the burden of driver gene mutations during maintenance therapy.	Week 24,48
Secondary	Hematologic remission	Week 48
Secondary	Spleen enlargement remission rate.	Week 24,48

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06734637/registered